Lyra Therapeutics Inc (LYRA): יחס מחיר להכנסות

Lyra Therapeutics, Inc. (LYRA) develops drug delivery systems for ENT organs, though it is currently struggling with a capital shortage following failed tests. The company's rolling P/S ratio helps assess market demand, while 1.40 determines the current status of this parameter. Growth prospects rely on the success of the LYR-210 drug and its potential FDA approval for expansion into the sinus treatment market.
Lyra Therapeutics, Inc. (LYRA) - פילוחי מדדים ודוחות פיננסיים

For the biotech startup Lyra Therapeutics, Inc. (LYRA), the P/S ratio serves as an indicator of market expectations regarding future revenue streams. This metric is calculated as the ratio of current market capitalization to total annual sales. Analyzing the history of P/S values allows for the identification of asset overvaluation in the absence of a commercial product. In the context of failed clinical trials and restructuring, this indicator highlights the speculative nature of the share price amid scaled-back operations.